Edition:
United States

DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

65.43EUR
28 Apr 2017
Change (% chg)

€0.32 (+0.49%)
Prev Close
€65.11
Open
€64.54
Day's High
€65.50
Day's Low
€64.52
Volume
26,441
Avg. Vol
28,172
52-wk High
€70.92
52-wk Low
€45.05

Latest Key Developments (Source: Significant Developments)

Dbv Technologies cash position shrinks to EUR 227.0 mln
Friday, 28 Apr 2017 01:30am EDT 

April 28 (Reuters) - DBV Technologies SA ::Cash and cash equivalents amounted to EUR 227.0 million ($246.5 million) as of March 31, 2017 compared to EUR 256.5 million as of Dec 31, 2016.  Full Article

DBV Technologies FY net loss widens to 114.5 mln euros
Wednesday, 15 Mar 2017 02:30am EDT 

DBV Technologies SA : FY net loss of amounts to 114.5 million euros versus a loss of 44.7 million euros a year ago . FY operating income is 9.1 million euros versus 6.2 million euros a year ago .Net cash flows from financing activities were 1.7 million euros in 2016 compared to 241.0 million euros in 2015.  Full Article

DBV Technologies announces completion of enrollment of the realise study in peanut allergic children
Friday, 10 Mar 2017 01:30am EST 

DBV Technologies Sa : Reg-DBV Technologies announces completion of enrollment of the realise study in peanut allergic children . Higher-Than-Expected patient demand leads to increased randomization target .Global PHASE III program results expected in second half 2017.  Full Article

DBV Technologies cash and cash equivalents down at 256.5 million euros as of December 31, 2016
Monday, 20 Feb 2017 01:31am EST 

Dbv Technologies SA :DBV’s cash and cash equivalents amounted to 256.5 million euros ($272.0 million) as of december 31, 2016, compared to 323.4 million euros as of December 31, 2015..  Full Article

DBV Technologies cash position at Sept. 30 down at 277.6 mln euros
Thursday, 3 Nov 2016 02:30am EDT 

DBV Technologies SA :Cash and cash equivalents as of Sept 30 amounted to 277.6 million euros ($308.6 million) compared to 323.4 million euros as of Dec 31, 2015.  Full Article

DBV Technologies announces expansion of clinical program for the treatment of peanut allergy
Tuesday, 2 Aug 2016 02:14am EDT 

DBV Technologies SA : Announced on Monday expansion of clinical program Viaskin Peanut for the treatment of peanut allergy .Topline results for trials are expected in the second half of 2017.  Full Article

DBV Technologies H1 net loss widens to 49.4 million euros
Thursday, 28 Jul 2016 01:30am EDT 

Dbv Technologies Sa : H1 net loss of 49.4 million euros ($54.66 million) versus loss of 14.5 million euros year ago . H1 cash position of 288.8 million euros versus 104.5 million euros year ago .H1 total income 4.8 million euros versus 3.2 million euros year ago‍​.  Full Article

DBV Technologies Sa files for stock shelf with U.S. SEC size undisclosed - SEC Filing
Wednesday, 27 Jul 2016 05:27pm EDT 

DBV Technologies Sa :Says files for stock shelf with U.S. SEC; size undisclosed - SEC filing.  Full Article

Dbv Technologies appoints Lucia Septién as chief medical officer
Tuesday, 5 Jul 2016 01:30am EDT 

Dbv Technologies SA :Announced appointment of Lucia Septién, M.D., as chief medical officer.  Full Article

DBV Technologies and Nestlé Health Science to collaborate on pediatric milk allergy test
Tuesday, 31 May 2016 01:02am EDT 

DBV Technologies SA : DBV Technologies and Nestlé Health Science form collaboration to develop and commercialize a novel diagnostic test for pediatric milk allergy .DBV is eligible to receive up to 100 million euros ($111.33 million) in potential development, registration and commercial milestones.  Full Article

More From Around the Web

BRIEF-Dbv Technologies cash position shrinks to EUR 227.0 mln

* Cash and cash equivalents amounted to EUR 227.0 million ($246.5 million) as of March 31, 2017 compared to EUR 256.5 million as of Dec 31, 2016 Source text for Eikon: Further company coverage: ($1 = 0.9207 euros) (Gdynia Newsroom)